164 related articles for article (PubMed ID: 17096291)
1. Metabolic diseases.
Balfe A; Perry L
IDrugs; 2006 Nov; 9(11):754-5. PubMed ID: 17096291
[No Abstract] [Full Text] [Related]
2. American Diabetes Association--69th Scientific sessions. Obesity management and treatment of type 2 diabetes: Part 1.
Kouremenou C
IDrugs; 2009 Aug; 12(8):463-4. PubMed ID: 19629873
[No Abstract] [Full Text] [Related]
3. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
Hodge RJ; Nunez DJ
Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
[TBL] [Abstract][Full Text] [Related]
4. Experimental drugs take aim at obesity.
Vastag B
JAMA; 2003 Apr; 289(14):1763-4. PubMed ID: 12684341
[No Abstract] [Full Text] [Related]
5. Early pharmacological intervention in newly diagnosed metabolic syndrome and type 2 diabetes.
Naruszewicz M
Przegl Lek; 2006; 63 Suppl 4():7-8. PubMed ID: 16967707
[No Abstract] [Full Text] [Related]
6. American Diabetes Association--68th Scientific Sessions. Clinical trial results.
Glah D
IDrugs; 2008 Aug; 11(8):556-8. PubMed ID: 18683087
[No Abstract] [Full Text] [Related]
7. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.
Sasaoka T; Wada T; Tsuneki H
Pharmacol Ther; 2006 Dec; 112(3):799-809. PubMed ID: 16842857
[TBL] [Abstract][Full Text] [Related]
8. [New therapies for type 2 diabetes mellitus].
Puig-Domingo M; Pellitero S
Med Clin (Barc); 2015 Jun; 144(12):560-5. PubMed ID: 25194974
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities.
Tang H; Yan Y; Feng Z; de Jesus RK; Yang L; Levorse DA; Owens KA; Akiyama TE; Bergeron R; Castriota GA; Doebber TW; Ellsworth KP; Lassman ME; Li C; Wu MS; Zhang BB; Chapman KT; Mills SG; Berger JP; Pasternak A
Bioorg Med Chem Lett; 2010 Oct; 20(20):6088-92. PubMed ID: 20832306
[TBL] [Abstract][Full Text] [Related]
10. All in one: Researchers create combination drugs for diabetes and obesity.
Chakradhar S
Nat Med; 2016 Jul; 22(7):694-6. PubMed ID: 27387879
[No Abstract] [Full Text] [Related]
11. Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
Harley EA; Levens N
Curr Opin Investig Drugs; 2003 Oct; 4(10):1179-89. PubMed ID: 14649209
[TBL] [Abstract][Full Text] [Related]
12. Exenatide. Amylin/Eli Lilly.
Giannoukakis N
Curr Opin Investig Drugs; 2003 Apr; 4(4):459-65. PubMed ID: 12808888
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in peptide-based therapy for Type 2 diabetes and obesity.
Conlon JM; Flatt PR; Bailey CJ
Peptides; 2021 Nov; 145():170652. PubMed ID: 34555424
[No Abstract] [Full Text] [Related]
14. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders.
Heal DJ; Gosden J; Smith SL
Br J Clin Pharmacol; 2009 Dec; 68(6):861-74. PubMed ID: 20002080
[TBL] [Abstract][Full Text] [Related]
15. Natural compound renews hope for diabetes and obesity therapeutic target.
Merk D; Schubert-Zsilavecz M
Future Med Chem; 2015; 7(7):833-5. PubMed ID: 26061101
[No Abstract] [Full Text] [Related]
16. Hypoglycemic agents in the management of type 2 diabetes mellitus.
Ho J; Leung AK; Rabi D
Recent Pat Endocr Metab Immune Drug Discov; 2011 Jan; 5(1):66-73. PubMed ID: 22074580
[TBL] [Abstract][Full Text] [Related]
17. Emergence of promising therapies in diabetes mellitus.
Akkati S; Sam KG; Tungha G
J Clin Pharmacol; 2011 Jun; 51(6):796-804. PubMed ID: 20705952
[TBL] [Abstract][Full Text] [Related]
18. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?
Flatt PR
Diab Vasc Dis Res; 2007 Jun; 4(2):151-3. PubMed ID: 17654450
[TBL] [Abstract][Full Text] [Related]
19. Two anti-obesity hopefuls and their safety.
Bello NT; Campbell SC
Expert Opin Drug Saf; 2012 Sep; 11(5):681-3. PubMed ID: 22788876
[No Abstract] [Full Text] [Related]
20. New options for drug treatment of obesity in patients with Type 2 diabetes.
Kennedy RL; Khoo EY
Diabet Med; 2005 Sep; 22 Suppl 4():23-6. PubMed ID: 16109016
[No Abstract] [Full Text] [Related]
[Next] [New Search]
